Tbc proteolytic breakdown of the amyloid precursor protein (APP) to neurotoxic amyloid-ß peptides in the brain has been recognized as a major pathological pathway in Alzheimer's disease (AD). Yet, the factors that control the processing of APP and their potential contribution to the common sporadic form of AD remain poorly understood. Here, we review recent findings from studies in patients and in animal models that led to the identification of a unique sorting receptor for APP in neurons, designated SORLA/SORL1, that emerges as a key player in amyloidogenic processing and as major genetic risk factor for AD.
INTRODUCTION
The amyloid hypothesis represents the major current concept to describe the cellular and pathological events underlying neurodegenerative Accepted: April 4,2010 Address for correspondence: Thomas E. Willnow Max-Delbrueck-Center for Molecular Medicine Robert-Roessle-Str. 10, D-l3125 Berlin, Germany Phone: +49-30-9406-2569; Fax: +49-30-9406-3382 E-mail: willnow@mdc-berlin.de processes in Alzheimer's disease (AD) /19/. Central to this hypothesis is the amyloid precursor protein (APP), a type-1 membrane protein expressed in many neuronal and non-neuronal cell types. In cells, including neurons in the brain, APP undergoes two alternative proteolytic processing pathways that generate multiple soluble as well as membrane-associated fragments from this polypeptide ( Figure 1A , inset). The physiological relevance of APP processing is a focus of intense investigation and numerous functions have been assigned to the precursor and its processing products ( Figure 1A ). In terms of neurodegeneration, the conversion of APP to a 40 to 42 amino acid amyloid-ß peptide (Aß) through sequential cleavage by -and -secretases is noteworthy. Aß forms neurotoxic oligomers and senile plaques, pathological hallmarks of AD /9,37,79/.
Evidence that the extent of proteolytic breakdown of APP to Aß is a determinant of onset and progression of AD comes from rare inheritable (familial) forms of the disease that are caused by defects in the genes encoding APP or presenilin-1 and -2, components of the -secretase complex /69/. Typically, these mutations are associated with an overall increase in Aß peptide production or with a shift towards generation of the more amyloidogenic variant Aß 42 . Also, carrying an extra copy of the APP gene as in trisomy 21 is invariably associated with occurrence of AD at an early age.
Despite APP processing being critical to AD development, our understanding of the underlying regulatory mechanisms is rather incomplete. Thus, the goal has been to identify neuronal factors that control the metabolism of APP and to determine whether alterations in these pathways contribute to the common sporadic forms of the disease that afflict 90% of all patients.
Key to understanding APP processing is the complex trafficking behavior of the precursor VOLUME 21, NO. 4 protein through the intracellular compartments of neurons that determine its processing fate ( Figure  IB ). Most APP molecules are cleaved by a-secretase at or near the plasma membrane to produce soluble (s)APPa. Some precursor molecules, however, are re-internalized from the cell surface and delivered to late endosomes for ß-secretase (and subsequent -secretase) processing to sAPPß and Aß ( Figure  IB ). The importance of regulated intracellular transport of APP for Aß production is underscored by findings that faulty trafficking of APP through endocytic and secretory compartments of the cell contributes to AD-related processes /30,50,55,72/. Recently, a breakthrough in solving the puzzle of APP transport and processing came with the identification of a neuronal sorting receptor for APP called sorting protein-related receptor with -type repeats (SORLA). Independent lines of evidence from histopathological analyses of individuals with sporadic AD, to epidemiological studies in patient cohorts, to investigations in cell VOLUME 21,NO. 4, 2010 and animal models all converged on this novel receptor as a chief regulator of APP processing. In this review, we will summarize the latest findings on the sorting receptor SORLA, which is now considered one of the most important risk factors in sporadic AD. Initially considered a rather conspicuous group of sorting proteins with unknown function, the mammalian receptors of the gene family recently surfaced as potential neuronal disease genes in a number of association studies in patients. These diseases encompass Alzheimer disease (AD) and other types of age-related dementias (SORLA, SORCS1) /36,16/, bipolar disorders (SORCS2) 747, and senescence of the nervous system (sortil in) /40/. The functional relevance of VPS 1 OP domain receptors for the nervous system was confirmed by studies that uncovered sortilin as a receptor for neurotrophins in the control of neuronal cell death 1261.
SORLA is a 250-kDa protein widely expressed in neurons throughout the mammalian CNS ( Figure 3A-D) . In the mouse, expression starts at mid-gestation but increases significantly in the postnatal and adult brain 1291. In both rodent and human adult brain tissue, expression of the receptoi is strongest in the cerebral and entorhinal cortex, hippocampus, cerebellum, and brain stem /11,45,537. At the subcellular level, immunoreactivity for the receptor is restricted to the somatodendritic compartment ( Figure 3E ), where it mainly localizes to intracellular vesicles in the perinuclear region ( Figure 3F Previously, several proteins were identified that bind to SORLA in vitro, including apolipoproteins (apo) E and A-V /23,49/, signaling molecules such as glial cell derived neurotrophic factor /80/ and platelet derived growth factor-BB /14/, as well as certain enzymes (e.g., lipoprotein upases) /23/. The physiological ligands for SORLA in the brain and the relevance of this receptor pathway for structural integrity and function of the CNS remained enigmatic. Still, based on the structural similarity to other sorting proteins and its predominant localization to the TON and early endosomes, a distinct function for SORLA in sorting target proteins between secretory and endocytic compartments of neurons seemed likely.
SORLA/SORL1, a risk gene in sporadic AD
The involvement of SORLA in AD was initially suggested by Lah and colleagues /65/, who used gene expression profiling to demonstrate low levels of SORLA transcript in lymphoblasts from patients with sporadic AD. The decreased mRNA levels coincided with a reduced expression of the receptor in the brain areas most vulnerable to neurodegeneration, including the frontal cortex and hippocampus, as shown by immunohistology. Expression of the receptor in other brain areas like the cerebellum was not affected /53/. Reduced amounts of SORLA in the brain were also found in individuals \vith mild cognitive impairment, a condition that may represent prodromal AD 7647. In contrast, normal expression of the receptor was documented in individuals with familial forms of AD 7117, suggesting that impaired receptor expression represents a primary event in sporadic AD rather than a secondary consequence of neurodegeneration. Loss of receptor expression also manifests itself in lower levels of SORLA degradation products in the cerebrospinal fluid of affected individuals 7417.
What could be the mechanism that determines SORLA levels in the brain and elsewhere in the organism? Evidence from association studies argues that the determination may lie in allelic receptor gene variants in the human population. As shown in a pioneering study by Rogaeva et al. 7617 REVIEWS IN THE NEUROSCIENCES Sub . v. Most SNPs in SORLl that are associated with sporadic AD cluster in two haplotype blocks in the 5'-and 3'-region of the gene ( Table 1) . As all SNPs in question are located in intronic regions or cause silent mutations, the mechanism whereby these variants predispose to sporadic AD remains unclear. In line with reduced mRNA and protein levels for SORLA in AD patients, genetic control of receptor expression seems a possibility. Nevertheless, a correlation between distinct SORLl genotypes and protein levels still awaits unambiguous documentation.
SORLA regulates intracellular transport and processing of APP
In the initial report implicating low levels of SORLA with occurrence of AD, a function for this orphan receptor in apoE clearance in brain parenchyma was proposed /65/. Although a role for SORLA in apoE catabolism cannot be ruled out, the predominant intracellular localization of the receptor and a poor endocytic capacity compared with classical apoE receptors (e.g., low-density lipoprotsin receptor) argue against such an activity 721,48,667.
An alternative function for SORLA that is relevant to AD was first reported by Andersen et al. 717 , who demonstrated that SORLA directly binds APP and thereby affects the intracellular transport and processing of the precursor protein. complement-type repeats in SORLA (see Figure 2 ) that forms a 1:1 stoichiometric complex with the carbohydrate-linked domain of APP 727. Binding to SORLA results in a sequestration of APP in the TGN and an impaired transition to the cell surface, effectively reducing the extent of APP cleavage through amyloidogenic and non-amyloidogenic pathways 71,53,667. Also, interaction with SORLA blocks access of ß-secretase to APP, further impairing amyloidogenic processing 7747. These initial observations in cultured cells established a negative correlation between SORLA activity and conversion of APP to Aß, providing a working hypothesis on why low levels of this receptor in some individuals may predispose to enhanced APP turnover and to sporadic AD 737.
Given the proposed role for SORLA in directing APP transport through neuronal compartments harboring secretase activities, the signals that govern intracellular trafficking of the receptor warrant particular attention. Like other members of the VPSlOP-domain receptor family, SORLA is produced as inactive precursor carrying a 53 amino acid pro-peptide at the amino terminus that is required to fold the receptor polypeptide properly 7237. Upon transport through the constitutive secretory pathway to the TGN, the pro-peptide is cleaved by convertases to produce the mature receptor 7237. From the TGN, newly synthesized SORLA moves to the cell surface where it exhibits rapid internalization that is mediated by an 'acidic cluster dileucine' motif in the cytoplasmic receptor domain 7487. Following internalization, SORLA molecules relocate from early endosomes back to the TGN, avoiding transit to late endosomal compartments. This step is unique and not seen with endocytic receptors that deliver their cargo to late endosomes before moving back to the plasma membrane. In contrast, internalized SORLA molecules do not return to the cell surface but rather appear to cycle between late secretory and early endocytic organelles 748,497.
What evidence has been found that the peculiar trafficking behavior identified for SORLA in Chinese hamster ovary or human embryonic kidney cells bears any relevance for AD? Firstly, the central role of the Golgi in APP metabolism is well appreciated as the processing of APP requires an efficient transit of the precursor through this organeile IM,Ml. Experimentally disrupting Golgi transition blocks APP processing /30,55/ whereas treatment that enhances membrane shunt from TGN to plasma membrane increases it /82/. Also, tempering with sorting of APP between endocytic and Golgi compartments reduces APP cleavage /68/. All the above argues for the existence of factors (such as SORLA) in control of APP sorting at the TGN. Secondly, targeting SORLA to the wrong intracellular compartment results in an accumulation of APP in the very same location and an altered processing fate. For example, the coexpression of APP with SORLA mutants that are not retained in the TGN but sequester at the plasma membrane causes a shunt of APP to the cell surface and a massive increase in amyloidogenic processing. This effect is likely due to an increased number of APP molecules undergoing endocytosis, a pre-requisite for Aß production 7667. Thirdly, several cytosolic adaptor proteins that regulate protein transport between early endosomes and TGN have been implicated in AD. Previously, their mode of action in APP metabolism remained unclear, but new findings that these adaptors control trafficking of SORLA provide the missing functional link. Two such adaptor complexes, GGAs and retromer, are discussed in the following.
CYTOSOLIC ADAPTOR PROTEINS IN CONTROL OF APP METABOLISM
The Golgi-localizing, -adaptin ear homology domain, ARF-interacting proteins (GGA1, GGA2, and GGA3) are three related adaptors that select cargo proteins at the TGN for transport to endosomes. The proteins bind a tetrapeptide motif Asp-Val-Pro-Met that is also present in the tail of SORLA 7257. A disruption of this binding motif impairs the proper recycling of SORLA and, consequently, alters APP processing 7667. Remarkably, previous studies have implicated GGA-1 in APP metabolism in as much as reduced expression of the adaptor enhances, whereas overexpression decreases Aß formation 7777. These effects are independent of a direct interaction between APP and GGAs, suggesting that SORLA may be required to tether both components 7787.
Also, decreased levels of GGA1 and GGA3 are seen in brain autopsy specimens from AD patients 776,787.
As well as altered anterograde sorting, defects in reverse (or retrograde) sorting from endosomes to the TGN have also been linked to abnormal APP transport. Retromer is a tetrameric adaptor complex composed of VPS35, VPS29, VPS26, and sorting nexin 1/2 that mediates the retrograde sorting of cargo (reviewed in 767,717). VPS35 and VPS26 are poorly expressed in AD brain autopsies 7737, and disruption of the Vps35 gene in mice results in memory deficits and synaptic dysfunctions associated with elevated Aß levels 7467. Given the interaction between mammalian retromer and SORLA 7467, defects in retromer-guided recycling of SORLA could be a cause of neurodegenerative processes 7517.
In conclusion, substantial experimental evidence from histopathological and cell biological studies suggest a model whereby SORLA acts as sorting receptor for APP at the TGN (Figure 4) . SORLA seems to prevent transport into the intracellular pathways required for processing, thereby acting as negative regulator of Aß production. Because it recognizes interaction motifs both in the extracellular 727 and in the intracellular domain of APP 7747, it is tempting to speculate that SORLA may not only sort the mature precursor but also soluble (sAPP) or membrane-associated fragments (C99, C83) thereof (see Figure 1 A) .
SORLA DEFICIENCY PROMOTES AMYLOIDOGENIC PROCESSING AND PLAQUE DEPOSITION
Transgenic mouse models have been instrumental in exploring the relevance of novel risk genes for amyloidosis and plaque burden, and associated memory deficits in vivo. Models with genetically altered SORLA expression have been no exception to this rule.
As shown by Andersen and colleagues 717 and by Rohe et al. 7627 in two different mouse models of targeted Sorll gene disruption, a loss of receptor activity results in the enhanced turnover of murine APP and, consequently, in a significant increase in amyloidogenic (sAPPß, Aß) and non-amyloidogenic-REVIEWS IN THE NEUROSCIENCES KS9MN596L (Swe) caused a two-to threefold increase in Aß formation and plaque load /10,627. Interestingly in both models, SORLA deficiency exacerbates early amyloid pathology, causing a forward shift in disease onset. This diseasepromoting effect is dependent on the gene dose as seen comparing animals with two (SorlT'*), one (Sorll'"), or no functional Sorll gene (Sorll"), providing further experimental evidence that SORLA levels in the human brain determine risk of AD /I 07.
As well as studying the effects of enhanced amyloid peptide formation, SORLA-deficient mouse models also enabled an analysis of the consequences of elevated levels of soluble APP products in the CNS. This question was particularly relevant given the proposed role for sAPPa as a stimulator of adult neurogenesis ( Figure 1A ) /7,34/. In line with this hypothesis, a significant increase in sAPPa levels in Sorll"' mice coincided with a profound stimulation of neuronal extracellular regulated kinase (ERK) signaling and with an enhanced adult neurogenesis in the subgranular zone of the hippocampus, providing in vivo support for the neurotrophic action of sAPPa/62/.
Taken together, studies on mouse models of human SORLA deficiency documented a role for the receptor not only in control of plaque burden but also in APP-dependent neuronal signaling and suggested a molecular explanation for the increased ERK activity and enhanced adult neurogenesis observed in some AD patients 112, 27 Concerning the pathways modulating SORLA activity, the intracellular domain of the receptor has been shown to be released by -secretase cleavage 1511 and to act as a represser of SORL1 transcription 161 ( Figure 5 ). Another regulatory pathway was uncovered by investigations of docosahexaenoic acid (DHA), an essential dietary -3 polyunsaturated fatty acid that is implicated in AD. Higher blood levels of DHA are positively correlated with reduced risk of neurodegeneration in large epidemiological studies /28/. Dietary DHA significantly improves cognition, protects from synaptic protein loss, and lowers plaque deposition in mouse models, apparently by reducing Aß production 715,39,547. A recent report showed that DHA markedly up-regulates SORLA expression in primary neurons and in mouse models in vivo, suggesting that the protective effects of dietary fish oil supplementation may, at least in part, act through induction ofSORLl 7427 ( Figure 5 ).
Last but not least, screening approaches in primary neurons identified brain-derived neurotrophic factor (BDNF) as a major inducer of Sorll that activates receptor gene transcription through ERK 7637 ( Figure 5 ). In line with a physiological role as inducer of Sorll, receptor expression was significantly impaired in mouse models with genetic (Bdnf "") or disease-related loss of BDNF activity in the brain (e.g., Huntingdon's disease) 7637. Intriguingly, the exogenous application of BDNF reduced Aß production in the brain of wildtype mice, but not in animals genetically deficient for Sorll. The findings suggest that the beneficial effects ascribed to BDNF in APP metabolism 7447 work through the induction of SORL1 encoding a negative regulator of neuronal APP processing 7637. Besides elucidating novel cellular pathways in control of SORL1 expression in the brain, the studies described above provide proof that interventions, such as dietary DHA intake or BDNF application, designed to raise receptor REVIEWS IN THE NEUROSCIENCES expression represent potential therapeutic approaches in the treatment of AD.
CONCLUSIONS
Recent years have witnessed the detailed clarification of the cellular pathways in control of APP processing and their potential contribution to neurodegenerative processes in patients. In particular, the functional characterization of SORLA/SORL1, a unique sorting receptor for APP, sheds light on a previously poorly understood process concerning the targeted transport of APP to distinct intraneuronal compartments harbouring the various secretase activities. The results from histopathological and epidemiologic studies in humans further substantiate the critical role of this receptor in sporadic AD. Although much still remains to be learned about this exciting pathway, SORLA/SORL1 certainly holds great promise as a novel biomarker and perhaps even as a new drug target in the treatment of this devastating disease.
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